AU2015208932C1 - (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors - Google Patents

(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors Download PDF

Info

Publication number
AU2015208932C1
AU2015208932C1 AU2015208932A AU2015208932A AU2015208932C1 AU 2015208932 C1 AU2015208932 C1 AU 2015208932C1 AU 2015208932 A AU2015208932 A AU 2015208932A AU 2015208932 A AU2015208932 A AU 2015208932A AU 2015208932 C1 AU2015208932 C1 AU 2015208932C1
Authority
AU
Australia
Prior art keywords
oxazepane
ethyl
cyano
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015208932A
Other languages
English (en)
Other versions
AU2015208932B8 (en
AU2015208932B2 (en
AU2015208932A1 (en
AU2015208932A8 (en
Inventor
Carl-Johan Aurell
Stephen Connolly
Kevin James Doyle
Graham Peter Jones
Staffan PO KARLSSON
Hans Roland Lonn
Jaqueline Anne Macritchie
Nicholas John Palmer
John Fritiof Ponten
Steven Swallow
Amanda Jane Van De Poel
David Wyn Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015208932(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2015208932A1 publication Critical patent/AU2015208932A1/en
Priority to AU2017200338A priority Critical patent/AU2017200338B2/en
Publication of AU2015208932B2 publication Critical patent/AU2015208932B2/en
Publication of AU2015208932B8 publication Critical patent/AU2015208932B8/en
Publication of AU2015208932A8 publication Critical patent/AU2015208932A8/en
Publication of AU2015208932C1 publication Critical patent/AU2015208932C1/en
Application granted granted Critical
Priority to AU2018202956A priority patent/AU2018202956B2/en
Priority to AU2019202675A priority patent/AU2019202675B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Epoxy Compounds (AREA)
AU2015208932A 2014-01-24 2015-01-23 (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors Active AU2015208932C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017200338A AU2017200338B2 (en) 2014-01-24 2017-01-18 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2018202956A AU2018202956B2 (en) 2014-01-24 2018-04-30 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2019202675A AU2019202675B2 (en) 2014-01-24 2019-04-17 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
US61/931,090 2014-01-24
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017200338A Division AU2017200338B2 (en) 2014-01-24 2017-01-18 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (5)

Publication Number Publication Date
AU2015208932A1 AU2015208932A1 (en) 2016-07-28
AU2015208932B2 AU2015208932B2 (en) 2017-02-16
AU2015208932B8 AU2015208932B8 (en) 2017-03-09
AU2015208932A8 AU2015208932A8 (en) 2017-03-09
AU2015208932C1 true AU2015208932C1 (en) 2017-05-25

Family

ID=52432834

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015208932A Active AU2015208932C1 (en) 2014-01-24 2015-01-23 (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
AU2017200338A Active AU2017200338B2 (en) 2014-01-24 2017-01-18 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2018202956A Active AU2018202956B2 (en) 2014-01-24 2018-04-30 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2019202675A Active AU2019202675B2 (en) 2014-01-24 2019-04-17 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017200338A Active AU2017200338B2 (en) 2014-01-24 2017-01-18 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2018202956A Active AU2018202956B2 (en) 2014-01-24 2018-04-30 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2019202675A Active AU2019202675B2 (en) 2014-01-24 2019-04-17 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Country Status (39)

Country Link
US (18) US9522894B2 (OSRAM)
EP (4) EP3744714B1 (OSRAM)
JP (7) JP6469711B2 (OSRAM)
KR (1) KR102417684B1 (OSRAM)
CN (2) CN110483492B (OSRAM)
AP (1) AP2016009322A0 (OSRAM)
AR (1) AR099177A1 (OSRAM)
AU (4) AU2015208932C1 (OSRAM)
BR (1) BR112016016224B1 (OSRAM)
CA (1) CA2935625C (OSRAM)
CL (1) CL2016001889A1 (OSRAM)
CR (1) CR20160327A (OSRAM)
CY (2) CY1120049T1 (OSRAM)
DK (3) DK3097086T3 (OSRAM)
DO (1) DOP2016000175A (OSRAM)
EA (1) EA032794B1 (OSRAM)
ES (3) ES3018635T3 (OSRAM)
FI (1) FI3744714T3 (OSRAM)
HK (1) HK1225730B (OSRAM)
HR (3) HRP20180116T1 (OSRAM)
HU (3) HUE038274T2 (OSRAM)
IL (3) IL246614B (OSRAM)
LT (3) LT3097086T (OSRAM)
MX (1) MX368840B (OSRAM)
MY (1) MY194850A (OSRAM)
NO (1) NO2699580T3 (OSRAM)
NZ (2) NZ734768A (OSRAM)
PE (1) PE20161218A1 (OSRAM)
PH (1) PH12016501439A1 (OSRAM)
PL (3) PL3097086T3 (OSRAM)
PT (3) PT3323814T (OSRAM)
RS (3) RS60639B1 (OSRAM)
SG (2) SG11201606052TA (OSRAM)
SI (3) SI3744714T1 (OSRAM)
SM (3) SMT201800058T1 (OSRAM)
TW (1) TWI690517B (OSRAM)
UY (1) UY35963A (OSRAM)
WO (1) WO2015110826A1 (OSRAM)
ZA (2) ZA201605856B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (OSRAM) 2014-01-24 2018-02-24
KR20230054480A (ko) * 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
FI3758708T3 (fi) * 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
AU2019305565A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
EP4048280A4 (en) * 2019-10-23 2023-11-15 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
EP4182700A4 (en) 2020-07-20 2024-11-13 Insmed Incorporated METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES
JP7657291B2 (ja) * 2020-08-26 2025-04-04 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ１の阻害剤として作用するニトリル誘導体及びその使用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN116157405A (zh) * 2020-12-04 2023-05-23 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
EP4329767A4 (en) * 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CA3236069A1 (en) * 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
US20250101011A1 (en) 2022-01-11 2025-03-27 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd Peptidyl nitrile compound and use thereof
CN118695864A (zh) * 2022-02-16 2024-09-24 英斯梅德股份有限公司 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
US20250163036A1 (en) 2022-02-22 2025-05-22 Haisco Pharmaceuticals Pte. Ltd. Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
JP2025506307A (ja) 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
EP4484414A1 (en) 2022-02-22 2025-01-01 Haisco Pharmaceuticals Pte. Ltd. Salt and crystal form of dipeptidyl peptidase inhibitor compound
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
EP4538277A4 (en) 2022-06-07 2025-10-08 Reistone Biopharma Company Ltd PHARMACEUTICALLY ACCEPTABLE SALT OF A BENZO[C]CHROMANE COMPOUND, POLYMORPHIC FORM AND USE OF A PHARMACEUTICALLY ACCEPTABLE SALT
TW202404960A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的多晶型及其製備方法和用途
AU2023296161A1 (en) 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound
US20250250232A1 (en) 2022-07-06 2025-08-07 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
CN119948034A (zh) * 2022-10-26 2025-05-06 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
IL321931A (en) * 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
EP4665717A2 (en) * 2023-02-15 2025-12-24 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
CN120957728A (zh) * 2023-03-23 2025-11-14 海思科医药集团股份有限公司 一种二肽基肽酶小分子抑制剂的药物组合物
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128324A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DE60131423T2 (de) 2000-09-08 2009-03-19 Prozymex A/S Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
DK1325910T3 (da) 2000-10-06 2008-11-10 Mitsubishi Tanabe Pharma Corp Aliphatiske nitrogenholdige femleddede ringforbindelser
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
MXPA04005263A (es) 2001-12-04 2004-10-11 Hoffmann La Roche 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa.
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
DK1633702T3 (da) 2003-05-30 2008-11-10 Prozymex As Proteaseinhibitorer
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GEP20094671B (en) 2004-06-29 2009-04-27 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
CA2611688A1 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
MX2010003263A (es) 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
AU2008334444B2 (en) 2007-12-12 2011-12-15 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
MX2011006108A (es) 2008-12-08 2011-11-18 Vm Pharma Llc Composiciones de inhibidores de los receptores tirosina quinasa.
US20100256194A1 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
ES2583091T3 (es) 2011-02-11 2016-09-19 Glaxosmithkline Intellectual Property Development Limited Inhibidores de catepsina C
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
CN104284895B (zh) 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
EP2970252B1 (en) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DK2970283T3 (da) 2013-03-14 2021-01-25 Boehringer Ingelheim Int Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
US8889708B2 (en) 2013-03-14 2014-11-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
WO2015032943A1 (en) 2013-09-09 2015-03-12 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (OSRAM) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN106456552A (zh) 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
EP3191487B1 (en) 2014-09-12 2019-08-07 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
MX370366B (es) 2014-11-14 2019-12-11 Boehringer Ingelheim Int Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4).
CA2978234C (en) 2015-03-05 2023-05-02 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20230054480A (ko) 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
FI3758708T3 (fi) * 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
AU2019305565A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
WO2020214855A1 (en) 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4329767A4 (en) 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
CA3236069A1 (en) 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN118695864A (zh) 2022-02-16 2024-09-24 英斯梅德股份有限公司 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128324A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750

Also Published As

Publication number Publication date
JP2025157389A (ja) 2025-10-15
US11117874B2 (en) 2021-09-14
HK1255870A1 (en) 2019-08-30
PH12016501439B1 (en) 2017-02-06
US10287258B2 (en) 2019-05-14
JP2021046423A (ja) 2021-03-25
DOP2016000175A (es) 2016-08-15
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
AU2019202675A1 (en) 2019-05-16
US20230033573A1 (en) 2023-02-02
SMT202500137T1 (it) 2025-05-12
US20240132455A1 (en) 2024-04-25
BR112016016224A2 (OSRAM) 2017-08-08
US11655221B2 (en) 2023-05-23
AU2015208932B8 (en) 2017-03-09
PE20161218A1 (es) 2016-11-27
HUE052421T2 (hu) 2021-04-28
US10669245B2 (en) 2020-06-02
ZA201605856B (en) 2020-02-26
LT3097086T (lt) 2018-02-26
US12054465B2 (en) 2024-08-06
AU2015208932B2 (en) 2017-02-16
AP2016009322A0 (en) 2016-07-31
PL3323814T3 (pl) 2020-10-19
JP7157791B2 (ja) 2022-10-20
DK3097086T3 (en) 2018-02-05
HRP20180116T1 (hr) 2018-03-23
EP3097086A1 (en) 2016-11-30
JP2025072423A (ja) 2025-05-09
JP2022096662A (ja) 2022-06-29
TW201612167A (en) 2016-04-01
SMT201800058T1 (it) 2018-03-08
KR102417684B1 (ko) 2022-07-05
EA032794B1 (ru) 2019-07-31
US11673871B2 (en) 2023-06-13
DK3323814T3 (da) 2020-08-03
HK1225730B (en) 2017-09-15
EP3323814B1 (en) 2020-05-13
US9522894B2 (en) 2016-12-20
US11814359B2 (en) 2023-11-14
HRP20201147T1 (hr) 2020-12-11
JP6804570B2 (ja) 2020-12-23
SI3097086T1 (en) 2018-04-30
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
JP6469711B2 (ja) 2019-02-13
DK3744714T3 (da) 2025-04-07
EP3744714B1 (en) 2025-01-15
US20240336582A1 (en) 2024-10-10
ZA201800431B (en) 2019-09-25
US11673872B2 (en) 2023-06-13
US20230069044A1 (en) 2023-03-02
PT3744714T (pt) 2025-04-07
US20210238152A1 (en) 2021-08-05
US20200017455A1 (en) 2020-01-16
JP2019070029A (ja) 2019-05-09
IL252836A0 (en) 2017-08-31
US11655224B2 (en) 2023-05-23
US20200247765A1 (en) 2020-08-06
EP4548972A2 (en) 2025-05-07
US20230116721A1 (en) 2023-04-13
EP4548972A3 (en) 2025-06-25
CN105980367B (zh) 2019-08-23
AU2019202675B2 (en) 2020-05-28
EP3097086B1 (en) 2017-12-13
LT3323814T (lt) 2020-10-26
SI3744714T1 (sl) 2025-05-30
CY1120049T1 (el) 2018-12-12
JP2017503832A (ja) 2017-02-02
AR099177A1 (es) 2016-07-06
CL2016001889A1 (es) 2016-12-09
US11655222B2 (en) 2023-05-23
US20150210655A1 (en) 2015-07-30
SG11201606052TA (en) 2016-08-30
US20230250071A1 (en) 2023-08-10
CA2935625C (en) 2022-10-18
CN110483492B (zh) 2023-07-21
US20230025351A1 (en) 2023-01-26
JP7714823B2 (ja) 2025-07-29
MY194850A (en) 2022-12-19
NZ722063A (en) 2017-09-29
US20230062646A1 (en) 2023-03-02
PL3097086T3 (pl) 2018-04-30
CR20160327A (es) 2016-10-20
AU2017200338A1 (en) 2017-02-02
AU2018202956A1 (en) 2018-05-17
US9815805B2 (en) 2017-11-14
TWI690517B (zh) 2020-04-11
LT3744714T (lt) 2025-04-10
EP3744714A1 (en) 2020-12-02
CN105980367A (zh) 2016-09-28
CY1123391T1 (el) 2021-12-31
US20170057938A1 (en) 2017-03-02
BR112016016224B1 (pt) 2023-02-23
AU2017200338B2 (en) 2018-03-01
ES3018635T3 (es) 2025-05-16
RS60639B1 (sr) 2020-09-30
AU2015208932A1 (en) 2016-07-28
NZ734768A (en) 2022-09-30
CA2935625A1 (en) 2015-07-30
US20230085620A1 (en) 2023-03-23
US20230115170A1 (en) 2023-04-13
MX2016009349A (es) 2016-10-13
MX368840B (es) 2019-10-18
US11655223B2 (en) 2023-05-23
SG10201701056QA (en) 2017-03-30
ES2658516T3 (es) 2018-03-12
AU2018202956B2 (en) 2019-05-09
US11680049B2 (en) 2023-06-20
EA201691375A1 (ru) 2017-01-30
JP2023156479A (ja) 2023-10-24
JP7628587B2 (ja) 2025-02-10
HUE070606T2 (hu) 2025-06-28
HRP20250302T1 (hr) 2025-04-25
CN110483492A (zh) 2019-11-22
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
JP7336563B2 (ja) 2023-08-31
PT3323814T (pt) 2020-08-05
PL3744714T3 (pl) 2025-09-08
SMT202000433T1 (it) 2020-09-10
PH12016501439A1 (en) 2017-02-06
AU2015208932A8 (en) 2017-03-09
US11667615B2 (en) 2023-06-06
SI3323814T1 (sl) 2020-10-30
EP3323814A1 (en) 2018-05-23
IL265611A (en) 2019-05-30
US20230278969A1 (en) 2023-09-07
KR20160111470A (ko) 2016-09-26
US20230028726A1 (en) 2023-01-26
RS66709B1 (sr) 2025-05-30
WO2015110826A1 (en) 2015-07-30
US20180251436A1 (en) 2018-09-06
NO2699580T3 (OSRAM) 2018-02-24

Similar Documents

Publication Publication Date Title
AU2015208932C1 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 FEB 2017

TH Corrigenda

Free format text: IN VOL 31 , NO 6 , PAGE(S) 931 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2015208932, UNDER INID (54) CORRECT THE TITLE TO READ (2S)-N-((1S)-1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS

Free format text: IN VOL 30 , NO 30 , PAGE(S) 4506 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2015208932, UNDER INID (54) CORRECT THE TITLE TO READ (2S)-N-((1S)-1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 FEB 2017

FGA Letters patent sealed or granted (standard patent)